Immune Dysfunction in Allergic Asthma

This study is currently recruiting participants.

Verified by University of New Mexico, September 2005

Sponsors and Collaborators:	University of New Mexico National Heart, Lung, and Blood Institute (NHLBI)
Information provided by:	University of New Mexico
ClinicalTrials.gov Identifier:	NCT00189228

Purpose

We are using anti-IgE to investigate the role of pulmonary mast cells in asthma.

Condition	Intervention
Asthma	Drug: anti-IgE Drug: Xolair

MedlinePlus related topics: Asthma

Drug Information available for: Omalizumab

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Diagnostic, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study
Official Title:	Not a Drug Trial. We Are Using Anti-IgE to Examine the Role of Pulmonary Mast Cells in Asthma

Further study details as provided by University of New Mexico:

Estimated Enrollment:

Detailed Description:

Subjects with mild allergic asthma are examined before, immediately after and 2 months after a course of treatment with anti-IgE. The following are examined: Allergen skin tests, allergen induced asthma, peripheral blood basophils, pulmonary bronchial mucosal mast cells.

Eligibility

Ages Eligible for Study:	18 Years to 45 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Mild asthma, adults -

Exclusion Criteria:

children. on inhaled or systemic steroids

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00189228

Contacts

Contact: Mark Schuyler, MD

505 272-4661

mschuyler@salud.unm.edu

Locations

United States, New Mexico
UNM HSC	Recruiting
Albuquerque, New Mexico, United States, 87131
Contact: Mark Schuyler, MD 505-272-4661 mschuyler@salud.unm.edu
Principal Investigator: Mark Schuyler, MD
Principal Investigator: Mark Schuyler, MD
Sub-Investigator: Mark Schuyler, MD

Sponsors and Collaborators

University of New Mexico

National Heart, Lung, and Blood Institute (NHLBI)

Investigators

Study Director:

Mark Schuyler, MD

UNM HSC

More Information

Study ID Numbers:	UNMSCOR, NHLBI P50-HL44253
Study First Received:	September 10, 2005
Last Updated:	September 10, 2005
ClinicalTrials.gov Identifier:	NCT00189228
Health Authority:	United States: Food and Drug Administration

Study placed in the following topic categories:

Hypersensitivity
Lung Diseases, Obstructive
Respiratory Tract Diseases
Lung Diseases

Hypersensitivity, Immediate
Asthma
Omalizumab
Respiratory Hypersensitivity

Additional relevant MeSH terms:

Immune System Diseases
Bronchial Diseases

ClinicalTrials.gov processed this record on January 16, 2009